Core Viewpoint - China Biotechnology Services (08037) has successfully completed the issuance of convertible bonds totaling $35 million, with all conditions of the subscription agreement met as of February 20, 2026 [1] Group 1: Convertible Bonds Issuance - The company issued convertible bonds with a principal amount of $35 million, completing the issuance as per the terms of the subscription agreement [1] - Prior to this issuance, there was an outstanding principal amount of $6 million from the 2024 convertible bonds, which can be converted into a total of 39.25 million shares at a conversion price of HKD 1.20 per share [1] - Following the completion of the new convertible bond issuance, the conversion price for the 2024 convertible bonds has been adjusted from HKD 1.20 to HKD 1.11 per share, effective from February 20, 2026 [1] Group 2: Share Issuance and Terms - The maximum number of shares to be issued upon full conversion of the 2024 convertible bonds is 42.432 million shares, effective from the completion date of the new convertible bond issuance [1] - All other terms of the 2024 convertible bonds remain unchanged despite the adjustment in the conversion price [1]
中国生物科技服务(08037)完成发行本金总额为3500万美元的可换股债券